PABLO
ROJO CONEJO
Profesor titular de universidad
University of Padua
Padua, ItaliaPublicaciones en colaboración con investigadores/as de University of Padua (30)
2024
-
Analytical treatment interruption in children living with HIV: position statement from the EPIICAL consortium
The Lancet HIV, Vol. 11, Núm. 10, pp. e700-e710
-
Early inflammation as a footprint of increased mortality risk in infants living with HIV from three African countries
Scientific Reports, Vol. 14, Núm. 1
-
Low unspliced cell-associated HIV RNA in early treated adolescents living with HIV on long suppressive ART
Frontiers in Immunology, Vol. 15
-
Penta Network: State-of-the-Art Research in Pediatric Human Immunodeficiency Virus
Clinics in Perinatology, Vol. 51, Núm. 4, pp. 925-933
-
Sustained aviremia despite anti-retroviral therapy non-adherence in male children after in utero HIV transmission
Nature Medicine, Vol. 30, Núm. 10, pp. 2796-2804
2023
-
Effective early antiretroviral therapy in perinatal-HIV infection reduces subsequent plasma inflammatory profile
Pediatric Research, Vol. 94, Núm. 5, pp. 1667-1674
-
Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial
The Lancet Child and Adolescent Health, Vol. 7, Núm. 10, pp. 718-727
-
Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV – Week 48 results of the randomised SMILE Penta-17-ANRS 152 clinical trial
eClinicalMedicine, Vol. 60
2022
-
Children living with HIV in Europe: do migrants have worse treatment outcomes?
HIV Medicine, Vol. 23, Núm. 2, pp. 186-196
-
Clinical, Virological and Immunological Subphenotypes in a Cohort of Early Treated HIV-Infected Children
Frontiers in Immunology, Vol. 13
-
Determinants of B-Cell Compartment Hyperactivation in European Adolescents Living With Perinatally Acquired HIV-1 After Over 10 Years of Suppressive Therapy
Frontiers in immunology, Vol. 13, pp. 860418
-
Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial
The Lancet HIV, Vol. 9, Núm. 5, pp. e341-e352
-
Machine learning outperformed logistic regression classification even with limit sample size: A model to predict pediatric HIV mortality and clinical progression to AIDS
PloS one, Vol. 17, Núm. 10, pp. e0276116
-
Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial
The Lancet HIV, Vol. 9, Núm. 9, pp. e638-e648
-
Optimizing the World Health Organization algorithm for HIV vertical transmission risk assessment by adding maternal self-reported antiretroviral therapy adherence
BMC public health, Vol. 22, Núm. 1, pp. 1312
2021
-
Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children
New England Journal of Medicine, Vol. 385, Núm. 27, pp. 2531-2543
-
Early ART initiation during infancy preserves natural killer cells in young European adolescents living with HIV (CARMA cohort)
Journal of the International AIDS Society, Vol. 24, Núm. 7
-
Faster Initial Viral Decay in Female Children Living with HIV
Journal of the Pediatric Infectious Diseases Society, Vol. 10, Núm. 5, pp. 674-676
-
ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing
BMC infectious diseases, Vol. 21, Núm. 1, pp. 5
-
Size of HIV-1 reservoir is associated with telomere shortening and immunosenescence in early-treated European children with perinatally acquired HIV-1
Journal of the International AIDS Society, Vol. 24, Núm. 11